Results 131 to 140 of about 2,007,881 (314)
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
GeoGebra: A reliable and free software for measuring acetabular cup anteversion on digitalized plain radiographs. [PDF]
Bachhal V +4 more
europepmc +1 more source
Coding Free Software, Coding Free States: Free Software Legislation and the Politics of Code in Peru [PDF]
Anita Chan
openalex +1 more source
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
The scale-free feature and evolving model of large-scale software systems
Yan Hong Dong +2 more
openalex +1 more source
Trends in Free, Libre, Open Source Software Communities: From Volunteers to Companies / Aktuelle Trends in Free-, Libre-, und Open-Source-Software-Gemeinschaften: Von Freiwilligen zu Unternehmen [PDF]
Jesús M. González-Barahona +1 more
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

